Biotechnology News
Press Releases from Biotechnology Companies
Newsroom
Biotechnology news releases from biotechnology companies published by Newsfile. Searches will return results from stories up to two years old.
-
Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics
This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated April 9, 2021 to its short form base prospectus dated March 31, 2021.Halifax, Nova Scotia--(Newsfile Corp. - January 26, 2023) - Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is...
Biotechnology, Health
2023-01-26 5:34 PM EST | Sona Nanotech Inc. -
Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office
Calgary, Alberta--(Newsfile Corp. - January 26, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth. "Your...
Biotechnology, Pharmaceuticals, Health
2023-01-26 3:27 PM EST | Hemostemix Inc. -
Bloom Burton & Co. Announces the 2023 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - January 25, 2023) - Bloom Burton & Co. ("Bloom Burton") is excited to announce the launch of the 2023 Bloom Burton Award. In addition, Bloom Burton is also announcing that this year's Bloom Burton Award Gala will be held at the Four Seasons Hotel Toronto on...
Technology, Biotechnology, Investment Banking, Health
2023-01-25 7:30 AM EST | Bloom Burton & Co. Inc. -
PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University...
Biotechnology, Pharmaceuticals, Health
2023-01-25 7:00 AM EST | PreveCeutical Medical Inc. -
Hemostemix Wins Arbitration Decision
Calgary, Alberta--(Newsfile Corp. - January 24, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the Arbitrator has dismissed Dr. Burchardt's claims for compensation and damages against the Company, set aside the Change of Control Agreement on the grounds that...
Biotechnology, Pharmaceuticals, Health
2023-01-24 9:00 AM EST | Hemostemix Inc. -
Awakn Life Sciences Initiates Investigative Study of Novel Formulation of (S)-ketamine to Assess Dissociative Effect
Toronto, Ontario--(Newsfile Corp. - January 24, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has initiated an investigative study to establish the dissociative effect of...
Technology, Biotechnology, Health
2023-01-24 7:30 AM EST | Awakn Life Sciences Corp. -
Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated
Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to report the validation of its ARM vaccine candidate in...
Biotechnology, Pharmaceuticals, Health
2023-01-24 3:15 AM EST | Defence Therapeutics Inc. -
Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs
Calgary, Alberta--(Newsfile Corp. - January 23, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it is hiring four new biotechnologists to re-establish the Company's production of ACP-01 in Montreal. The Company is hiring an experienced autologous stem cell therapy Manufacturing...
Biotechnology, Pharmaceuticals, Health
2023-01-23 9:37 AM EST | Hemostemix Inc. -
Global Hemp Group Announces Execution of Exclusive Licensing Agreement for the Intellectual Property of Apollon Formularies PLC Covering the United States, Canada, and Mexico
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - GLOBAL HEMP GROUP INC. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG) ("GHG" or the "Company") is pleased to announce that further to the Company's announcement of January 11, 2023 regarding the execution of the binding LOI with Apollon Formularies Plc - (AQSE:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2023-01-23 9:09 AM EST | Global Hemp Group Inc. -
PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned...
Biotechnology, Pharmaceuticals, Health
2023-01-23 7:00 AM EST | PreveCeutical Medical Inc. -
RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023,...
Biotechnology, Pharmaceuticals, Health
2023-01-23 3:15 AM EST | Defence Therapeutics Inc. -
Cloud DX Announces Private Placements of up to an Aggregate of $5.5 Million with Lead Orders of $1.5 Million
Waterloo, Ontario--(Newsfile Corp. - January 20, 2023) - Cloud DX Inc. (TSXV: CDX) (OTCQB: CDXFF) ("Cloud DX" or the "Corporation"), is pleased to announce a private placement financing of up to 17,857,142 units of the Corporation (the "Units") at a price of $0.14 per Unit for aggregate gross proceeds of...
Technology, Biotechnology, Healthcare and Hospitals
2023-01-20 8:17 PM EST | Cloud DX Inc. -
Defence To Present at The 9th Annual Immuno-Oncology 360 Summit in New-York February 7-10, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2023) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce that Defence will attend, from February 7-10, 2023,...
Biotechnology, Pharmaceuticals, Health
2023-01-20 4:30 PM EST | Defence Therapeutics Inc. -
Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation
Calgary, Alberta--(Newsfile Corp. - January 19, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation. The Letter of Commitment confirms that the MUHC Foundation will...
Biotechnology, Pharmaceuticals, Health
2023-01-19 11:28 AM EST | Hemostemix Inc. -
Therma Bright Inc. Invests in Ischemic Stroke Blood Clot Retriever Technology Company Inretio Inc. based in Israel
Toronto, Ontario--(Newsfile Corp. - January 19, 2023) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma Bright" or the "Company"), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce that it has signed a SPA (Share Purchase...
Technology, Biotechnology, Health
2023-01-19 8:00 AM EST | Therma Bright Inc. -
Moss to Commence Trading on the Canadian Securities Exchange on January 19, 2023
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Moss Genomics Inc. (CSE: MOSS) ("Moss" or the "Company"), a consumer genomics and gut microbiome company based in Vancouver, British Columbia, is pleased to announce that its common shares have been approved for listing on the Canadian Securities Exchange (the...
Biotechnology
2023-01-18 7:55 PM EST | Moss Genomics Inc. -
Nova Mentis Appoints Derek Ivany as Executive Chairman
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the appointment of Derek Ivany to...
Technology, Biotechnology, Health
2023-01-18 8:30 AM EST | Nova Mentis Life Science Corp. -
Advanced Proteome Therapeutics Announces Its Proposed Plan of Arrangement
Burnaby, British Columbia--(Newsfile Corp. - January 17, 2023) - Advanced Proteome Therapeutics Corporation (TSXV: APC) (FSE: 0E81) ("APC" or the "Company") is pleased to announce that the Supreme Court of British Columbia (the "Court") has issued an interim order (the "Interim Order") on January 16, 2023 in connection with the...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2023-01-17 2:39 PM EST | Advanced Proteome Therapeutics Corp. -
GoodCap Announces the Appointment of Dr. Laura Targownik to Its Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - January 17, 2023) - GoodCap Pharmaceuticals Inc. ("GoodCap" or the "Company"), is pleased to announce the appointment of Dr. Laura Targownik, MD, to its Scientific Advisory Board.Dr. Targownik is currently a Clinician Researcher in the Mount Sinai Hospital Inflammatory Bowel Disease Clinic and is a member...
Biotechnology, Pharmaceuticals, Health, Psychedelics
2023-01-17 9:00 AM EST | GoodCap Pharmaceuticals Inc. -
BioHarvest Sciences Inc. Appoints Dr. George Garibaldi to Its Scientific Board of Advisors
Dr. Garibaldi's 40 years of experience brings industry-leading pharmaceuticals development expertise to the Scientific Board of Advisors.His appointment demonstrates the company's resolve to leverage its biotechnology platform for enabling drugs development.Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - January 17, 2023) - BioHarvest Sciences Inc. (CSE:
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Cultivator
2023-01-17 7:30 AM EST | BioHarvest Sciences Inc.